Cargando…
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretrov...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383194/ https://www.ncbi.nlm.nih.gov/pubmed/37515298 http://dx.doi.org/10.3390/v15071612 |
_version_ | 1785080847567683584 |
---|---|
author | Maggi, Paolo Ricci, Elena Delfina Martinelli, Canio Vito De Socio, Giuseppe Vittorio Squillace, Nicola Molteni, Chiara Masiello, Addolorata Orofino, Giancarlo Menzaghi, Barbara Bellagamba, Rita Vichi, Francesca Celesia, Benedetto Maurizio Madeddu, Giordano Pellicanò, Giovanni Francesco Carleo, Maria Aurora Cascio, Antonio Parisini, Andrea Taramasso, Lucia Valsecchi, Laura Calza, Leonardo Rusconi, Stefano Sarchi, Eleonora Martini, Salvatore Bargiacchi, Olivia Falasca, Katia Cenderello, Giovanni Ferrara, Sergio Di Biagio, Antonio Bonfanti, Paolo |
author_facet | Maggi, Paolo Ricci, Elena Delfina Martinelli, Canio Vito De Socio, Giuseppe Vittorio Squillace, Nicola Molteni, Chiara Masiello, Addolorata Orofino, Giancarlo Menzaghi, Barbara Bellagamba, Rita Vichi, Francesca Celesia, Benedetto Maurizio Madeddu, Giordano Pellicanò, Giovanni Francesco Carleo, Maria Aurora Cascio, Antonio Parisini, Andrea Taramasso, Lucia Valsecchi, Laura Calza, Leonardo Rusconi, Stefano Sarchi, Eleonora Martini, Salvatore Bargiacchi, Olivia Falasca, Katia Cenderello, Giovanni Ferrara, Sergio Di Biagio, Antonio Bonfanti, Paolo |
author_sort | Maggi, Paolo |
collection | PubMed |
description | Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (−0.36, p < 0.0001) than in the RPV cohort (−0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (−14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART. |
format | Online Article Text |
id | pubmed-10383194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103831942023-07-30 Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting Maggi, Paolo Ricci, Elena Delfina Martinelli, Canio Vito De Socio, Giuseppe Vittorio Squillace, Nicola Molteni, Chiara Masiello, Addolorata Orofino, Giancarlo Menzaghi, Barbara Bellagamba, Rita Vichi, Francesca Celesia, Benedetto Maurizio Madeddu, Giordano Pellicanò, Giovanni Francesco Carleo, Maria Aurora Cascio, Antonio Parisini, Andrea Taramasso, Lucia Valsecchi, Laura Calza, Leonardo Rusconi, Stefano Sarchi, Eleonora Martini, Salvatore Bargiacchi, Olivia Falasca, Katia Cenderello, Giovanni Ferrara, Sergio Di Biagio, Antonio Bonfanti, Paolo Viruses Article Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based regimen impacted metabolic and hepatic safety. The analysis included 551 antiretroviral treatment (ART)-experienced people living with HIV (PLWH), starting RPV-based or DOR-based regimens with viral load < 200 copies/mL, baseline (T0), and at least one control visit (6-month visit, T1). We enrolled 295 PLWH in the RPV and 256 in the DOR cohort. At T1, total cholesterol (TC), low-density lipoprotein-C (LDL-C), and triglycerides significantly decreased in both DOR and RPV cohorts, while high-density lipoprotein-C (HDL-C) only decreased in RPV-treated people. Consistently, the TC/HDL-C ratio declined more markedly in the DOR (−0.36, p < 0.0001) than in the RPV cohort (−0.08, p = 0.25) (comparison p = 0.39). Similar trends were observed when excluding the PLWH on lipid-lowering treatment from the analysis. People with normal alanine aminotransferase (ALT) levels showed a slight ALT increase in both cohorts, and those with baseline ALT > 40 IU/L experienced a significant decline (−14 IU/L, p = 0.008) only in the DOR cohort. Lipid profile improved in both cohorts, and there was a significant reduction in ALT in PLWH with higher-than-normal baseline levels on DOR-based ART. MDPI 2023-07-23 /pmc/articles/PMC10383194/ /pubmed/37515298 http://dx.doi.org/10.3390/v15071612 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maggi, Paolo Ricci, Elena Delfina Martinelli, Canio Vito De Socio, Giuseppe Vittorio Squillace, Nicola Molteni, Chiara Masiello, Addolorata Orofino, Giancarlo Menzaghi, Barbara Bellagamba, Rita Vichi, Francesca Celesia, Benedetto Maurizio Madeddu, Giordano Pellicanò, Giovanni Francesco Carleo, Maria Aurora Cascio, Antonio Parisini, Andrea Taramasso, Lucia Valsecchi, Laura Calza, Leonardo Rusconi, Stefano Sarchi, Eleonora Martini, Salvatore Bargiacchi, Olivia Falasca, Katia Cenderello, Giovanni Ferrara, Sergio Di Biagio, Antonio Bonfanti, Paolo Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting |
title | Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting |
title_full | Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting |
title_fullStr | Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting |
title_full_unstemmed | Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting |
title_short | Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting |
title_sort | lipids and transaminase in antiretroviral-treatment-experienced people living with hiv, switching to a doravirine-based vs. a rilpivirine-based regimen: data from a real-life setting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383194/ https://www.ncbi.nlm.nih.gov/pubmed/37515298 http://dx.doi.org/10.3390/v15071612 |
work_keys_str_mv | AT maggipaolo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT riccielenadelfina lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT martinellicaniovito lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT desociogiuseppevittorio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT squillacenicola lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT moltenichiara lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT masielloaddolorata lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT orofinogiancarlo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT menzaghibarbara lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT bellagambarita lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT vichifrancesca lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT celesiabenedettomaurizio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT madeddugiordano lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT pellicanogiovannifrancesco lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT carleomariaaurora lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT cascioantonio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT parisiniandrea lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT taramassolucia lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT valsecchilaura lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT calzaleonardo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT rusconistefano lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT sarchieleonora lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT martinisalvatore lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT bargiacchiolivia lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT falascakatia lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT cenderellogiovanni lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT ferrarasergio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT dibiagioantonio lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting AT bonfantipaolo lipidsandtransaminaseinantiretroviraltreatmentexperiencedpeoplelivingwithhivswitchingtoadoravirinebasedvsarilpivirinebasedregimendatafromareallifesetting |